Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL284647 | 0.97 | ALDH1A1 (0.50) | ALDH1A1LMNAHSD17B10MEN1NPC1 | |
| SCHEMBL4957929 | 0.94 | ALDH1A1 (0.48) | ALDH1A1LMNAHSD17B10MEN1NPC1 | |
| Hydrochloric Acid SCHEMBL27554398 | 0.94 | ALDH1A1 (0.48) | ALDH1A1LMNAHSD17B10MEN1NPC1 | |
| SCHEMBL21981164 | 0.94 | ALDH1A1 (0.48) | ALDH1A1LMNAHSD17B10MEN1NPC1 | |
| SCHEMBL28145904 | 0.94 | ALDH1A1 (0.48) | ALDH1A1LMNAHSD17B10MEN1NPC1 | |
| SCHEMBL29207090 | 0.94 | ALDH1A1 (0.48) | ALDH1A1LMNAHSD17B10MEN1NPC1 | |
| SCHEMBL28904001 | 0.94 | ALDH1A1 (0.48) | ALDH1A1LMNAHSD17B10MEN1NPC1 | |
| SCHEMBL27524668 | 0.90 | ALDH1A1 (0.43) | ALDH1A1LMNAHSD17B10MEN1NPC1 | |
| Hexane SCHEMBL5202053 | 0.87 | CA2 (0.52) | ALDH1A1LMNAHSD17B10MEN1NPC1 | |
| Phosphonic Acid SCHEMBL7247578 | 0.87 | ALDH1A1 (0.42) | ALDH1A1LMNAHSD17B10MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 869 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117758374-A | On-DNA alpha-hydroxy olefin lead compound and synthesis method thereof | 康龙化成(宁波)科技发展有限公司 | 2024-03-26 | — | — | CN | claimed |
| CN-114853822-A | Oligonucleotide-disulfide and synthetic method thereof | 康龙化成(宁波)科技发展有限公司 | 2022-08-05 | — | — | CN | claimed |
| EP-1438437-B1 | METHOD FOR THE DETECTION OF CYTOSINE METHYLATION IN IMMOBILISED DNA SAMPLES | EPIGENOMICS AG (DE) | 2009-04-22 | — | — | EP | claimed |
| US-4005129-A | OXALATE ESTERS | ATLANTIC RICHFIELD COMPANY (US) | 1977-01-25 | — | — | US | claimed |
| US-12637672-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2026-05-26 | — | — | US | disclosed |
| EP-3801553-B1 | PRODRUGS OF FULVESTRANT | KASHIV BIOSCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260076989-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD (SG) | 2026-03-19 | — | — | US | disclosed |
| US-20260009012-A1 | ENGINEERED PHOSPHOPENTOMUTASE VARIANT ENZYMES | CODEXIS, INC. (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250320494-A1 | INHIBITORS OF EXPRESSION AND/OR FUNCTION | E-THERAPEUTICS PLC (GB) | 2025-10-16 | — | — | US | disclosed |
| US-20250313836-A1 | CHIRAL DESIGN | WAVE LIFE SCIENCES LTD (SG) | 2025-10-09 | — | — | US | disclosed |
| US-12421509-B2 | Engineered phosphopentomutase variant enzymes | CODEXIS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250281622-A1 | FN3 DOMAIN-siRNA CONJUGATES AND USES THEREOF | Aro Biotherapeutics Company | 2025-09-11 | — | — | US | disclosed |
| EP-0212951-A2 | Labelled nucleic acids | AMOCO CORPORATION (US) | 1987-03-04 | — | — | EP | disclosed |
| EP-0210021-A2 | Carbonic anhydrase inhibitor-tagged nucleic acid probes | SISKA DIAGNOSTICS,INC. (US) | 1987-01-28 | — | — | EP | disclosed |
| EP-0209996-A2 | Nucleic acid probes comprising N4 -(substituted amino)cytidines | SISKA DIAGNOSTICS,INC. (US) | 1987-01-28 | — | — | EP | disclosed |
| CN-85104701-A | Produce the method for useful matter | — | 1986-12-17 | — | — | CN | disclosed |
| US-4552764-A | Peptides for control of intestinal motility | RESEARCH CORPORATION (US) | 1985-11-12 | — | — | US | disclosed |
| EP-0097373-A2 | Modified labeled nucleotides and polynucleotides and methods of preparing, utilizing and detecting same | ENZO BIOCHEM, INC. (US) | 1984-01-04 | — | — | EP | disclosed |
| US-4281142-A | Imidazolecarboxaldehydes | HOFFMANN-LA ROCHE INC. (US) | 1981-07-28 | — | — | US | disclosed |
| US-4194049-A | 2-[[2-Methyl-1-[2-benzoyl(or benzyl)phenyl]-1H-imidazol-5-yl]methyl]-1H-isoindole-1,3(2H)-diones | HOFFMANN-LA ROCHE INC. (US) | 1980-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260009012-A1 | ENGINEERED PHOSPHOPENTOMUTASE VARIANT ENZYMES | PPME1, PPA1, ITPA | ALDH1A1 3787/4885LMNA 4597/4885HSD17B10 2615/4885 |
| US-20260076989-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | NSUN2, TLR9, MSR1 | ALDH1A1 4430/4885LMNA 1684/4885HSD17B10 3942/4885 |
| US-12637672-B2 | Oligonucleotide compositions and methods thereof | UPF1, SMN1; SMN2, RNGTT | ALDH1A1 3106/4885LMNA 870/4885HSD17B10 4756/4885 |
| US-20250320494-A1 | INHIBITORS OF EXPRESSION AND/OR FUNCTION | SERPINC1, TFPI2, SERPINB1 | ALDH1A1 1796/4885LMNA 2527/4885HSD17B10 1395/4885 |
| US-20250281622-A1 | FN3 DOMAIN-siRNA CONJUGATES AND USES THEREOF | FN1, ITGB3, FNIP1 | ALDH1A1 4563/4885LMNA 1379/4885HSD17B10 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.